Exelixis' and Roche's combined colon cancer therapy failed — 4 insights

Exelixis and Roche were testing a combined late-stage colon cancer therapy and found that although it was safe, it did not improve overall survival, Investor's Business Daily reports.

Here's what you should know.

1. The therapy consisted of Exelixis' Cotellic combined with Roche's Tecentriq.

2. The combination was safe, but ineffective.

3. The failure caused Exelixis stock to slide to a new 11-month low, hitting $18.56 May 10.

4. For Roche, this is the latest of several failed therapies, which is dissuading investors.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast